NCT02735915View on ClinicalTrials.gov

Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older

PHASE3CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

April 11, 2016

Primary Completion Date

August 28, 2017

Study Completion Date

October 8, 2018

Conditions
Herpes Zoster
Interventions
BIOLOGICAL

Herpes Zoster Vaccine GSK1437173A

Intramuscular injection

Trial Locations (7)

13347

GSK Investigational Site, Berlin

45359

GSK Investigational Site, Essen

68161

GSK Investigational Site, Mannheim

97070

GSK Investigational Site, Würzburg

500 01

GSK Investigational Site, Hradec Králové

SE-631 88

GSK Investigational Site, Eskilstuna

SE-751 85

GSK Investigational Site, Uppsala

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY